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Abstract
Background: Morphine-induced tolerance is associated with the spinal neuroinflammation. The aim of this study
was to explore the effects of oral administration of the pioglitazone, the peroxisome proliferator activated receptor
gamma (PPAR-γ) agonist, on the morphine-induced neuroinflammation in the lumbar region of the male Wistar rat
spinal cord.
Results: Co-administration of the pioglitazone with morphine not only attenuated morphine-induced tolerance,
but also prevented the up-regulation of pro-inflammatory cytokines (tumor necrosis factor alpha, interleukin-
1beta, and interleukin 6) and nuclear factor-kappa B activity. Administration of the GW-9662 antagonized the
above mentioned effects of the pioglitazone.
Conclusions: It is concluded that oral administration of the pioglitazone attenuates morphine-induced tolerance and
the neuroinflammation in the lumbar region of the rat spinal cord. This action of the pioglitazone may be, at least in
part, due to an interaction with the spinal pro-inflammatory cytokine expression and the nuclear factor-kappa B activity.
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Background
Our recent studies demonstrated that administration of
the pioglitazone prevents the morphine antinociception
tolerance and withdrawal symptoms in the rats [1, 2].
Morphine is one of the most widely used analgesics for
relieving severe pain. Despite the known side-effects of
the opioids, the clinical utility of opioid analgesics is often
hampered by the development of analgesic tolerance that
necessitates dose escalation. To date, several mechanisms
have been proposed to contribute in the morphine anal-
gesic tolerance such as: the N-methyl-D-aspartate (NMDA)
receptors activation [3], down-regulation of the spinal glu-
tamate transporters [4], the spinal glial activation, and the
release of the pro-inflammatory cytokines [5] and apoptosis
[6]. It is highly confirmed that morphine activates the glial
cells during prolonged exposure [7, 8]. In this regard, it is
recognized that chronic administration of the morphine
augments the production of the pro-inflammatory cyto-
kines including: tumor necrosis factor alpha (TNF-α),
interleukin (IL)-1β and IL-6 in the central nervous system
(CNS) [5]. The glial derived pro-inflammatory cytokines
increase the neuronal excitability [8], sensitize the pain
transmission neurons [9], up-regulated the NMAD recep-
tors [10], down-regulated the glutamate transporters [4]
and oppose opioid-induced analgesia [5].
Accumulating evidences have suggested that targeting
of the spinal glial activation [11], hampering the pro-
inflammatory cytokines expression [12] inhibition of the
nuclear factor kappa B (NF-κB) activity [13] and antagoniz-
ing the pro-inflammatory cytokine receptors [5] may be
considered as important strategies for preventing the mor-
phine analgesic tolerance. In this regard, Shen et al. demon-
strated that the intrathecal administration of the etanercept
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restored the antinociceptive effect of the morphine by in-
hibition the spinal pro-inflammatory cytokines expression
[12]. Moreover, Tai et al. indicated that the amitriptyline at-
tenuated the morphine analgesic tolerance by inhibition of
the spinal pro-inflammatory cytokine expression [14].
The peroxisome proliferator activated receptor gammas
(PPAR-γ) are the orphan receptors in the CNS and the
immune system, which target several downstream genes,
involved in inflammation [15]. The pioglitazone is one of
the PPAR-γ agonists with a good profile of blood brain
barrier penetration [16]. Pioglitazone exerts its anti-
inflammatory effects through suppression of the glial
cells functions [17, 18], and regulation of the NF-κB activ-
ity [19]. Recently, the pioglitazone has received increasing
attention in addiction [20]. The clear evidence for a role of
pioglitazone in the abused drug addiction came from of
Stopponi et al.’s current study. The later study showed that
pioglitazone inhibits the alcohol consumption and hampers
the expression of the alcohol withdrawal signs [21].
One part of our recently published finding indicated that
pioglitazone attenuated the development of tolerance, shift-
ing the first day of established tolerance from the 17th day
in the control group to the 32th day (Fig. 1a, b). On the
other hand administration of the GW-9662, the select-
ive PPAR- γ antagonist, reversed the above mentioned
effect of the pioglitazone [2].
Considering the central role of the inflammation in the
morphine-induced tolerance and the anti-inflammatory
feature of the pioglitazone, we considered to investigate
the role of the pioglitazone in the morphine pharmacology
focusing on the relation of the spinal pro-inflammatory
cytokines changes and the attenuating effect of the pio-
glitazone on the morphine-induced tolerance.
Methods
Animals
Male Wistar rats (200–250 g) were received from the Pas-
teur Institute (Tehran, Iran). The animals were maintained
under standard temperature (22 ± 0.5 °C) and light in con-
ditions (12-h light/12-h darkness) with free access to food
and water for 2 days before experiment. All experiments
were executed in accordance with the Guide for Care and
Use of Laboratory Animals of Tabriz University of Medical
Sciences, Tabriz, Iran (National Institutes of Health Publi-
cation No 85–23, revised 1985).
Drugs
Morphine sulfate (Daroupakhsh Company, Tehran, Iran)
was dissolved in the normal saline and injected intraperi-
toneally (i.p). The pioglitazone hydrochloride (Zahravi
Company, Tabriz, Iran) was suspended in the propyl-
ene glycol and distilled water (60:40) with a few drops
of dimethylsulfoxide and administered orally 30 min before
morphine injection. The PPAR-γ antagonist, GW-9662
(Sigma Chemical Company, USA), was dissolved in the
pioglitazone vehicle and administrated subcutaneously (s.c).
In this regard, the GW-9662 was administrated 30 min be-
fore the pioglitazone oral administration. Pioglitazone,
morphine and GW-9662 doses were chosen based on
our previous studies [1, 2].
Experimental groups
Rats were divided into four experimental groups (n = 6–8)
randomly. The experimental groups consisted of one saline
treated group and three morphine treated groups. The sa-
line treated group (vehicle) was only treated with saline and
the vehicle. Thirty minutes before morphine injection, rats
Fig. 1 The effect of pioglitazone (5, 10, 20, 40 mg/kg; a) and its combination with GW-9662 (2 mg/kg; b) on the completion of morphine analgesic
tolerance [2]
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in the control group were received vehicle (0.5 mL) and the
pioglitazone group were received pioglitazone (40 mg/kg)
orally. To evaluate the role of PPAR-γ in pioglitazone
effects on the morphine antinociception tolerance and
the spinal pro-inflammatory cytokines, the GW-9662
(2 mg/kg, s.c) was administered 30 min before pioglita-
zone administration in the GW-treated group.
Induction of tolerance to the analgesic effect of morphine
In order to induce tolerance to the analgesic effect of the
morphine, the rats were received morphine (10 mg/kg, i.p)
once a day until the tolerance completion on the control
group [2]. It is worth noting that the experiment was
carried out until day 18 of the experiment (one day after
tolerance completion of the control group).
Assessment of nociception
A radiant heat tail flick apparatus (model 37360; Ugo Basile,
Italy) was used for assessment of the nociception. To this
aim, the animals were gently restrained by hands during
the test and the light beam (power intensity =5) was fo-
cused on 3–4 cm from the tail distal end. The tail flick la-
tency was considered as the time between the tail exposure
to the radiant heat and the tail withdrawal. The baseline tail
flick latency was determined for each rat and designed as
the baseline latency. The baseline latency was the average
of three measurements and the intensity of the light was
adjusted so that the baseline latencies were 2–3 s. A cut-off
time (15 s) was imposed to prevent the tissue damage. The
tail flick response latencies were defined as the percentage
of the maximal possible effect (MPE%) using the following
equation:
MPE% ¼ Post drug latency − Baseline latency
Cutoff time − Baseline latency
 100
The baseline latency was determined daily before each
drug or vehicle administration. Moreover, vehicle or pi-
oglitazone were gavage to the rats. It is worth noting
that, thirty minutes before the pioglitazone administration,
the rats were received the GW-9662. Thirty minutes later,
the morphine (10 mg/kg) or the saline were injected
intraperitoneally and finally the post-drug latency was
measured after 30 min.
Tissue preparation
On the eighteenth day (one day after the tolerance com-
pletion of the control group), two hours after the last
dose of the morphine administration, the animals were
rapidly (<1 min) sacrificed. Consequently, the lumbar spinal
cord segments were removed, weighed, frozen in the liquid
nitrogen and stored at -80 °C until being used for cytokine
and NF-κB p 65 measurements. The frozen tissue samples
were homogenized in ice-cold lysis buffer (500 mM
Tris–HCl, pH 7.4, 150 mM NaCl, EDTA 0.5 mM, n-octyl-
ß-D-glucopyranoside 1.5 % w/v) containing a complete pro-
tease inhibitor cocktail (Roche Cat # 11873 580 001) and
were centrifuged at 14,000 rpm for 10 min at 4 °C [22].
The supernatants were used for analysis of TNF-α, IL-1ß
and IL-6.
Measurement of the spinal pro-inflammatory cytokine level
The spinal level of cytokines were determined using com-
mercial ELISA kit specified for the rat IL-6 and TNF-α
(eBioscience, Australia) and IL-1β (Glory Science Co., Ltd,
USA) according to the manufacturer instruction. The re-
sults were expressed as picogram (p) per gram tissue.
Determination of the spinal NF-κ B p65 activity
Briefly, the weighted lumbar spinal tissue (40 mg) was cut
into small pieces and in the presence of phosphatase in-
hibitors (Cayman, item number # 10009305), detergent
(Nonidet P-40 10 %; Cayman, item number # 600009) and
the hypotonic buffer (Cayman, item number # 10009301),
tissue was homogenized using pre-chilled Dounced
homogenizer. Hypotonic buffer causes the cells to swell
with breakage in the cell membrane by detergent, allowing
access to the cytoplasm fraction while maintaining the in-
tegrity of the nuclear membrane. Subsequently, the nuclei
fraction was separated from the cytoplasmic fraction by
centrifugation. Then nuclear fraction was resuspended in
ice-cold nuclear extraction buffer (Cayman, item number #
10009304) containing protease (Cayman, item number #
10009303) and phosphatase inhibitors. The suspension was
vortexed; followed by gentle rocking on ice for 15 min
(This step was repeated for five times). Then, the suspen-
sion was centrifuged at the 14000 rpm for 10 min at 4 °C.
The supernatant was used for determining total protein
concentration and NF-κB p 65 activity. A specific double
stranded DNA sequence containing the NF-κB response
element was immobilized onto the bottom of 96 well plates
(Cayman, item number # 10007889). NF-κB contained in a
nuclear extract, binds specifically to the NF-κB response
element. NF-κB (p65) was detected by addition of specific
primary antibody directed against NF-κB (p65). A second-
ary antibody conjugated to HRP was added to provide a
sensitive colorimetric readout at 450 nm.
Statistical analysis
Data were analyzed by the Statistical Product for Social
Sciences (SPSS version 11.5). All data obtained are pre-
sented as the mean of six to eight rats ± SEM (standard
error of the mean). For the behavioural data and the
spinal NF-κB p65 activity, the difference between groups
was determined by the one-way analysis of variance
(ANOVA) followed by the Newman-Keuls test. The spinal
cytokines levels, obtained from ELISA, were analyzed,
using the one-way ANOVA followed by the Tukey’s post
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hoc test. The differences amongst means were considered
statistically significant if p value < 0.05.
Results and discussion
Effect of pioglitazone on the development of
morphine-induced tolerance
The maximum analgesic effect of the morphine was re-
corded on the first day of the experiment. After that the
morphine tail-flick latency threshold was progressively de-
creased to the base line levels in the control group and de-
veloped the tolerance on day 17 (Fig. 2a). Co-administration
of the pioglitazone (40 mg/kg) with the morphine could
hamper the morphine analgesic tolerance development
significantly (p < 0.001; Fig. 2a). Moreover, as depicted
in Fig. 2a administration of the GW-9662 (2 mg/kg)
30 min before administration of the pioglitazone, reversed
the anti-tolerance effect of the pioglitazone (p < 0.05), sig-
nificantly. On the day 18 of the experiments, the %MPE of
the morphine in the rats that treated with the pioglitazone
was 73 % which was significantly (p < 0.001) more that
the %MPE of the control group (Fig. 2b). However,
daily co-administration of PPAR-γ antagonist with the
pioglitazone prevented the pioglitazone effect on the
%MPE of morphine significantly (p < 0.05). These find-
ings were consistent with our previous study [2] in that
the oral administration of the pioglitazone (5, 10, 20 and
40 mg/kg) dose-dependently prevented the morphine
antinociception tolerance completion (Fig. 1a) and the
GW-9662 antagonized the anti-tolerance effect of the
pioglitazone in the rat (Fig. 1b).
Cytokines levels
The spinal levels of TNF-α, IL-1β and IL-6 increased
significantly in the control group compared with the
saline-vehicle treated group (p < 0.001 for all). As shown in
the Fig. 3, concurrently oral administration of the pioglita-
zone (40 mg/kg) significantly attenuated the increases in
the spinal TNF-α (p < 0.001), IL-1β (p < 0.001) and IL-6
(p < 0.01) protein levels compared with the control group.
Moreover, administration of the GW-9662 (2 mg/kg) thirty
minutes prior to the pioglitazone (40 mg/kg) reversed
the pioglitazone effect on the spinal TNF-α (p < 0.05),
IL-1β (p < 0.05) and IL-6 (p > 0.05) protein levels.
Effect of pioglitazone or GW-9662 on the spinal NF-κB p65
activity
As compared to the saline treated animals, morphine in-
creased (319 %) the spinal NF-κB p65 activity (p < 0.001),
significantly. As depicted in the Fig. 4, co-administration
of the morphine with the pioglitazone (40 mg/kg) attenu-
ated the spinal NF-κB p65 activity significantly compared
with the control group (p < 0.001). Subcutaneous injection
of the selective PPAR-γ antagonist, before the pioglitazone
administration, prevented the pioglitazone inhibitory ef-
fect on the NF-κB p65 activity and enhanced its activity by
74 % (p < 0.01) versus the pioglitazone (40 mg/kg) plus
morphine treated group.
In the present study we aimed to investigate the effect of
the pioglitazone as a PPAR-γ agonist on the inflammatory
responses developed through tolerance to morphine
analgesia. Our results suggested that the pioglitazone
(40 mg/kg) administration in morphine multiple-injected
rats, attenuated the development of the morphine anal-
gesic tolerance and we suggest that the improvement in
the morphine effectiveness seen by the pioglitazone is re-
lated to the pioglitazone action on the PPAR-γ resulting in
reduction of the pro-inflammatory responses. Moreover,
our study indicated that the spinal pro-inflammatory
cytokines play an important role in the development of
morphine antinociception tolerance. Besides, our recently
finding indicated that morphine augments both pro-
inflammatory cytokines (e.g., TNF-α, IL-1β and IL-6)
and NF-κB activity in the cerebral cortex of the rat, which
was consistent with the behavioural manifestation of
Fig. 2 The tail-flick latency was measured every day 30 min after i.p injection of saline or morphine (a). The antinociceptive effect of 10 mg/kg
(i.p) morphine on the day 18 in the groups that received saline, vehicle, pioglitazone (40 mg/kg), or GW-9662 (2 mg/kg) for 17 days (b). All date
points are expressed as the mean ± SEM. ***: p < 0.001 compared with morphine-vehicle treated animals. ≠: p < 0.05 compared with GW-9662
(2 mg/kg) treated animals. (Sal: Saline; Mor: morphine; Pio: pioglitazone; GW: GW-9662; Veh: vehicle; MPE%: maximal possible effect)
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morphine analgesic tolerance. However, concurrent admin-
istration of the pioglitazone (40 mg/kg) hampered these ef-
fects of the morphine [23].
Morphine-induced tolerance is associated with a sig-
nificant increase in the glial derived pro-inflammatory
cytokines in the rat spinal cord. It has been established
that targeting these cytokines [12], attenuating the glial
activity [11], antagonizing the spinal IL-1β receptors [5]
or interrupting the NF-κB activity [13] lead to improving
the morphine effectiveness and delaying the onset of
analgesic tolerance. It is also indicated that the PPAR-γ
agonists exert anti-inflammatory effects through the sup-
pression of the glial cell function and the regulation of the
activity of different transcription factors such as the
NF-κB [15, 17, 24]. Our recently study indicated that
pioglitazone attenuates the development of tolerance
in the rat [2]. Moreover, acute administration of pio-
glitazone attenuated the naloxone induced morphine
withdrawal syndrome in rat [1].
This is highly confirmed that in inflammatory processes,
the NF-κB is the most important transcription factor,
which controls the promoter regions of the different pro-
inflammatory cytokine genes those are implicated in the
morphine antinociception tolerance. The NF-κB p65 ac-
tivity at the lumbar spinal cord in the pioglitazone-treated
rats have been measured and compared with equivalent
measurements in the morphine-injected animals. We
assessed whether the NF-κB might play a functional role
in the impact of the pioglitazone on the improvement of
the morphine effectiveness. Herein, we report that oral ad-
ministration of the pioglitazone reduced the NF-κB p65
activity in the lumbar spinal cord. Consistent with these
results, Wang et al. (2010) reported that interruption in
NF-κB transcription activity ameliorated the morphine
analgesic tolerance development [13]. Furthermore, the
GW-9662 as the PPAR-γ antagonist reversed the inhibi-
tory effects of the pioglitazone on the NF-κB p65 activity.
This finding was in consistent with the recent findings
that the pioglitazone inhibited the NF-κB activity and
the GW-9662 reversed its effects [19]. One of the nu-
merous mechanisms that support the pro-inflammatory
cytokines involvement in the morphine analgesic tolerance,
is association of increased glial derived pro-inflammatory
cytokines levels in the rat spinal cord to tolerance [5]. The
glial derived pro-inflammatory cytokines lead to the mor-
phine analgesic tolerance either directly or indirectly.
Directly these inflammatory substances initiate the down-
stream signaling transduction cascade and aggravate the
release of prostaglandins, nitric oxide and glutamate there-
fore, promote pain transmission [25]. Indirectly, the glial
derived pro-inflammatory cytokines down regulate the
glutamate transporters and produce a high glutamate
amount in synapses [4, 10]. Earlier studies have reported
that the TNF-α leads to an immense activation of the glu-
tamatergic system in the rat spinal cord through down-
regulation of the glutamate transporters and exocytosis of
the NMDA receptors [10]. Hyperactivation of the gluta-
matergic system resulted in enhancing the intracellular
mechanisms of morphine tolerance [26]. It is worth noting
that activation of the NMDA receptors is associated with
the morphine analgesic tolerance [3]. We found that the
Fig. 3 The levels of spinal pro-inflammatory cytokines in the different groups. Cytokines (a: TNF-α, b: IL-1β, c: IL-6) following 17 days treatment
with morphine (10 mg/kg). All date points are expressed as the mean ± SEM. (Sal: Saline; Mor: morphine; Pio: pioglitazone; GW: GW-9662;
Veh: vehicle).
Fig. 4 The activity of NF-κB p65 in different experimental group on
day 18. All data points are expressed as the mean ± SEM. (Sal: Saline;
Mor: morphine; Pio: pioglitazone; GW: GW-9662; Veh: vehicle)
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pioglitazone has a remarkable ability in inhibiting the pro-
duction of pro-inflammatory cytokines including TNF-α,
IL-1β and IL-6 where the GW-9662 reverses its effect.
In addition to the anti-inflammatory properties of the
pioglitazone, it is found that the pioglitazone is capable
of reducing the NMDA receptors mediated calcium current
and potential conferring the neuroprotection [27]. In this
regard, it is widely indicated that the NMDA receptor an-
tagonist can inhibit the morphine tolerance.
Conclusions
Administration of the pioglitazone with the morphine
attenuated both development of the morphine tolerance
and the spinal pro-inflammatory cytokines expression.
However, these effects of the pioglitazone were abolished
by the PPAR-γ selective antagonist (GW-9662). The
effects of the pioglitazone might be caused, at least in
part, through the PPAR-γ on suppression of the NF-κB
activity in the spinal cord, which resulted in negative
regulation of the IL-6, IL-1β and TNF-α expression.
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